A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda ® in Participants With Stage II and III Melanoma

Conditions: Melanoma Interventions: Drug: GME751; Drug: Keytruda - EU; Drug: Keytruda - US Sponsors: Sandoz Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials